Drug Study – ATROPINE SULFATE
Acts by selectively blocking all muscarinic responses to acetylcholine (ACh), whether excitatory or inhibitory. Selective depression of CNS relieves rigidity and tremor of Parkinson’s syndrome. Antisecretory action (vagolytic effect) suppresses sweating, lacrimation, salivation, and secretions from nose, mouth, pharynx, and bronchi. Blocks vagal impulses to heart with resulting decrease in AV conduction time, increase in heart rate and cardiac output, and shortened PR interval.
Classifications:
AUTONOMIC NERVOUS SYSTEM AGENT; ANTICHOLINERGIC (PARA-SYMPATHOLYTIC); ANTIMUSCARINIC
INDICATION:
Adjunct in symptomatic treatment of GI disorders (e.g., peptic ulcer, pylorospasm, GI hypermotility, irritable bowel syndrome) and spastic disorders of biliary tract. Relaxes upper GI tract and colon during hypotonic radiography. Ophthalmic Use: To produce mydriasis and cycloplegia before refraction and for treatment of anterior uveitis and iritis. Preoperative Use: To suppress salivation, perspiration, and respiratory tract secretions; to reduce incidence of laryngospasm, reflex bradycardia arrhythmia, and hypotension during general anesthesia. Cardiac Uses: For sinus bradycardia or asystole during CPR or that is induced by drugs or toxic substances (e.g., pilocarpine, beta-adrenergic blockers, organophosphate pesticides, and Amanita mushroom poisoning); for management of selected patients with symptomatic sinus bradycardia and associated hypotension and ventricular irritability; for diagnosis of sinus node dysfunction and in evaluation of coronary artery disease during atrial pacing.
